Skip to main content

RNAi / siRNA Deal Benchmarks in Cardiovascular

Median Upfront
$697M
Range: $379M - $1.0B
Total Deal Value
$3.5B
Range: $2.3B - $4.7B
Royalty Rate
9.8% - 19.5%
Tiered up to 23.5%
Dev Milestones
$618M
Range: $418M - $820M
Model Your Deal

Market Analysis

RNAi / siRNA therapies in cardiovascular have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in cardiovascular is $697M, with total deal values reaching $3.5B. Development milestones average $618M, while regulatory milestones contribute $786M.

The cardiovascular rnai / sirna landscape is characterized by moderate competitive intensity with renewed interest in novel mechanisms and genetic targets. RNA-based therapies, PCSK9 approaches, and novel anticoagulants are driving a resurgence in cardiovascular deal activity. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna cardiovascular deals range from 9.8% to 19.5% at the base tier, with tiered escalation reaching 13.8%-23.5% on blockbuster sales. Commercial milestones averaging $1.4B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna cardiovascular licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in cardiovascular average $697M in upfront payments, with a range of $379M to $1.0B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna cardiovascular transactions?
The median total deal value for Phase 2 rnai / sirna assets in cardiovascular is $3.5B, ranging from $2.3B to $4.7B. This includes development milestones ($618M), regulatory milestones ($786M), and commercial milestones ($1.4B).
What royalty rates are standard for rnai / sirna deals in cardiovascular?
Base royalty rates for rnai / sirna cardiovascular transactions range from 9.8% to 19.5%, with tiered escalations reaching 13.8%-23.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna cardiovascular deals?
RNAi / siRNA cardiovascular deals allocate approximately 80% of total deal value to milestones. Development milestones ($618M) make up the largest share, followed by commercial milestones ($1.4B) and regulatory milestones ($786M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Cardiovascular

View

Monoclonal Antibody in Cardiovascular

View

RNAi / siRNA in Oncology

View

RNAi / siRNA in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough